Rediff Logo
 Money
Line
Channels: Astrology | Broadband | Contests | E-cards | Money | Movies | Romance | Search | Weather | Wedding | Women
Partner Channels: Auctions | Auto | Bill Pay | IT Education | Jobs | Lifestyle | Technology | Travel
Line
Home > Money > Reuters > Report
April 30, 2001 		Feedback  
  Money Matters

 -  Business Special
 -  Business Headlines
 -  Corporate Headlines
 -  Columns
 -  IPO Center
 -  Message Boards
 -  Mutual Funds
 -  Personal Finance
 -  Stocks
 -  Tutorials
 -  Search rediff

    
      

 
Reuters
 Search the Internet
         Tips
 Sites: Finance, Investment
E-Mail this report to a friend
Print this page

Dr Reddy's ties up with UK firm for tests

Indian drug firm Dr Reddy's Laboratories said on Monday that it had selected Britain's Simbec Research Limited, a clinical research organisation, to carry out trials for a new drug it had developed.

A Dr Reddy's statement said Simbec would soon begin toxicology trials for DRF 4832, used in the treatment of cardiovascular disease.

The company had earlier licensed further development of two diabetes drugs to Danish firm Novo Nordisk.

Those drugs are in late phase II of clinical development. Phase II trials are devoted to testing the efficacy of a drug.

Dr Reddy's Labs shares on Monday fell 0.52 per cent to Rs 1,121.50, while the Sensex gained 2.82 per cent on the day.

Back to top
(c) Copyright 2000 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Tell us what you think of this report